Balversa (Erdafitinib) belongs to the class of medications called protein kinase inhibitors. It is used to treat urothelial cancer, a type of cancer of the bladder, when the cancer has been previously treated with chemotherapy which is no longer working, and has either spread to other parts of the body or cannot be removed by surgery.
Available form
Tablet
Dosage
Manufacturer
Janssen
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
The recommended starting dose of Balversa (Erdafitinib) is 8 mg taken by mouth, once daily. After 14 to 21 days, your doctor may increase or decrease your dose, depending on the results of blood tests and how well the medication is tolerated.
Balversa (Erdafitinib) should be taken once daily at approximately the same time every day. It may be taken with food or on an empty stomach. Swallow the tablets whole, do not chew or crush the tablets.
If you vomit after taking a dose, do not take another dose. Take the next dose at the regularly scheduled time.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important to take Balversa (Erdafitinib) exactly as prescribed by your doctor.
If you miss a dose, take it as soon as possible and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store Balversa (Erdafitinib) at room temperature, protect it from light and moisture, and keep it out of the reach of children.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Balversa (Erdafitinib). If you are concerned about side effects, discuss the risks and benefits of Balversa (Erdafitinib) with your doctor.
The following side effects have been reported by at least 1% of people taking Balversa (Erdafitinib). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Balversa (Erdafitinib).
3 mg
Each yellow, round, biconvex, film-coated tablet, debossed with "3" on one side and "EF" on the other side, contains 3 mg of Balversa (Erdafitinib). Nonmedicinal ingredients: croscarmellose sodium, magnesium stearate (from vegetable source), mannitol, meglumine, and microcrystalline cellulose; film-coating: glycerol monocaprylocaprate Type I, iron oxide yellow, polyvinyl alcohol partially hydrolyzed, sodium lauryl sulfate, talc, and titanium dioxide.
4 mg
Each orange, round, biconvex, film-coated tablet, debossed with "4" on one side and "EF" on the other side, contains 4 mg of Balversa (Erdafitinib). Nonmedicinal ingredients: croscarmellose sodium, magnesium stearate (from vegetable source), mannitol, meglumine, and microcrystalline cellulose; film-coating: glycerol monocaprylocaprate Type I, iron oxide yellow, iron oxide red, polyvinyl alcohol partially hydrolyzed, sodium lauryl sulfate, talc, and titanium dioxide.
5 mg
Each brown, round, biconvex, film-coated tablet, debossed with "5" on one side and "EF" on the other side, contains 5 mg of Balversa (Erdafitinib). Nonmedicinal ingredients: croscarmellose sodium, magnesium stearate (from vegetable source), mannitol, meglumine, and microcrystalline cellulose; film-coating: ferrosoferric oxide/iron oxide black, glycerol monocaprylocaprate Type I, iron oxide yellow, iron oxide red, polyvinyl alcohol partially hydrolyzed, sodium lauryl sulfate, talc, and titanium dioxide.
Do not take Balversa (Erdafitinib) if you are allergic to Balversa (Erdafitinib) or any ingredients of the medication.
There may be an interaction between Balversa (Erdafitinib) and any of the following:
If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Medications other than those listed above may interact with Balversa (Erdafitinib). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Balversa (Erdafitinib).
Eye problems: People taking Balversa (Erdafitinib) may experience eye problems and vision changes. If you experience changes to your vision such as cloudiness, blurred vision or vision loss, contact your doctor immediately.
Phosphorus levels: Balversa (Erdafitinib) can cause higher than normal levels of phosphate in the blood. Your doctor will test for the amount of phosphate in your blood with blood tests while you are taking Balversa (Erdafitinib).
Pregnancy: Balversa (Erdafitinib) should not be taken during pregnancy. Balversa (Erdafitinib) may cause severe harm to a developing baby if it is taken by the mother while she is pregnant. Female partners of men taking Balversa (Erdafitinib) should not become pregnant. Both females and males must use a reliable method of birth control (e.g., condoms, birth control pill) during treatment and for at least 3 months after treatment is finished. If you become pregnant while taking Balversa (Erdafitinib), contact your doctor immediately.
Breast-feeding: Balversa (Erdafitinib) may pass into breast milk. If you are a breast-feeding mother and are taking Balversa (Erdafitinib), it may affect your baby. Due to the potential for serious harm to a baby if they are exposed to Balversa (Erdafitinib), breast-feeding mothers are advised not use Balversa (Erdafitinib).
Children: The safety and effectiveness of using Balversa (Erdafitinib) have not been established for children.
price lookup
Total no. of dose(s)
Manufacturer
Insurance coverage
Dosage
*Actual pricing may differ. Medication is only available by prescription. The cost may be subsidised by your provincial or private health plan.
price details
Total (CAD)
--*
Drug info not available
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
Your region
,
Pocketpills is licensed by
Accreditation No
#
Pharmacy Manager
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer